Medicines report's finding on opioid prescriptions suggests policies and public pressure paying off

19 April 2018

A huge reduction in opioid prescriptions is the most striking feature of the latest report from the IQVIA Institute for Human Data Science on medicine usage and spending in the USA.

The fact that the opioid figures are being highlighted as the major takeaway from the report on US medicines as a whole reflects the importance attached to the issue.

Opioid dosage volume — as defined by morphine milligram equivalents (MMEs) — declined by 12% in 2017, marking the largest annual drop in more than 25 years of measurement of the quantity dispensed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK